MedTrace Logo

A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function

NCT00674856 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2009-01-28

No results posted yet for this study

Summary

To study the pharmacokinetics and safety of naproxcinod in patients with impaired renal function

Conditions

  • Renal Failure

Interventions

DRUG

naproxcinod

750mg

Sponsors & Collaborators

  • NicOx

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-09-30
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674856 on ClinicalTrials.gov